LivaNovaLIVN +2.94%76 FCF Yield % is 3.51 as of Jun. 27, 2026, which is 110% above its 10-year median of 1.67. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.48 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 855 Medical Devices & Instruments companies, LivaNova ranks better than 73.1% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
LivaNova FCF Yield % Related Terms
LivaNova FCF Yield % Historical Data
* Premium members only.
The historical data trend for LivaNova's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LivaNova's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's FCF Yield % distribution charts can be found below:
* The bar in red indicates where LivaNova's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova (LIVN) has a FCF Yield % of 3.51 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on LivaNova and its competitors. This is 110% above median its historical median of 1.67. According to the industry distribution chart, LivaNova ranks #230 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 26.9%.
Is LivaNova's FCF Yield % too high?
LivaNova's current FCF Yield % of 3.51 is 110% above median its 10-year median of 1.67. Based on the distribution chart, LivaNova ranks #230 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LivaNova has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's FCF Yield % compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #230 out of 855 companies for FCF Yield %. This puts LivaNova in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on LivaNova and its competitors. LivaNova's current FCF Yield % is 3.51, which is 110% above median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.48, compared to a current price of $83.39 — trading 33.5% above its estimated fair value. The current FCF Yield % is 3.51, which is 110% above median its 10-year median of 1.67. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For LivaNova (LIVN), the current FCF Yield % is 3.51 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (LIVN) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of $83.39 is trading 33.5% above its estimated GF Value™ of $62.48.
GuruFocus considers LivaNova to be Significantly Overvalued.
Key valuation signals for LIVN:
FCF Yield %: 3.51 (110% above median its 10-year median of 1.67)
GF Value™: $62.48 vs. price of $83.39 (33.5% above fair value)
No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score
Get the complete analysis for LIVN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIVN has been successfully added to your 
